Global Cephalosporin Drugs Market, by Generation (First-generation Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), by Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), by Formulation (Oral ( Tablets, Capsules, and Liquid) and Injection), by Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 14,240.0 million in 2018, and is projected to exhibit a CAGR of 3.8% over the forecast period (2019 - 2026), as highlighted in a new report published by.

Increasing research on antibiotic resistance, support of several governments for pharmacogenomics-based drug discovery, and high number of strategic partnerships for launch and distribution of cephalosporin drugs in different countries are some of the major factors driving growth of the cephalosporin drugs market. Various organizations are focused on receiving approvals from the Food and Drug Administration (FDA) for clinical trials in order to develop and launch new generation drugs for the treatment of bacterial infections. For instance, in April 2017, Basilea Pharmaceutica Ltd. announced that it has reached agreement with the U.S. FDA on Special Protocol Assessments (SPAs) for its two planned phase III clinical studies of Basilea's antibiotic ceftobiprole (fifth generation).

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/cephalosporin-drugs-market-2893

The two studies will evaluate ceftobiprole for the treatment of Staphylococcus aureus bacteremia (bloodstream infections) and acute bacterial skin and skin structure infections. Manufacturers in the cephalosporin drugs market are focusing on strategic partnerships in order to gain significant market share.

For instance, in April 2018, Basilea Pharmaceutica Ltd. announced that its partner Avir Pharma Inc. launched Basilea's hospital antibiotic Zevtera (ceftobiprole) in Canada. Furthermore, in May 2018, Basilea Pharmaceutica Ltd. announced that its partner Hikma Pharmaceuticals LLC launched Basilea's hospital antibiotic Zevtera (ceftobiprole) in Saudi Arabia.

Browse 53 Market Data Tables and 50 Figures spread through 236 Pages and in-depth TOC on "Global Cephalosporin Drugs Market, By Generation (First-generation, Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), By Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), By Formulation (Oral (Tablets, Capsules, and Liquid) and Injection), By Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic infection)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2893

Furthermore, increasing funding from several governments for research and development regarding antibiotic resistance is expected to contribute to growth of the cephalosporin drugs market. For instance, in September 2018, National Institutes of Health (NIH) granted US$ 9.4 million for establishing the Center for Biomedical Research Excellence (COBRE) to address the worldwide threat of drug-resistant pathogens to The Miriam Hospital in Rhode Island, U.S.

Key Takeaways of the Global Cephalosporin Drugs Market:

The global cephalosporin drugs market is expected to witness a CAGR of 3.8% during the forecast period (2019–2026), owing to increasing research & development activities related to cephalosporin drugs and new product launches.

Among generations, the third-generation cephalosporin segment is expected to account for major revenue share in 2026. This is owing to increasing product launches in the third-generation cephalosporin drugs. For instance, in March 2017, Pfizer Inc. launched the antibiotic Zavicefta (Third-generation cephalosporin) in the U.K. and Germany for the treatment of aerobic gram-negative infections caused by resistant bacteria.

Major players operating in the global cephalosporin drugs market include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2893

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737